Literature DB >> 6442931

Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model.

F Krijzer, M Snelder, D Bradford.   

Abstract

Freely moving rats were implanted with cortical, caudal, thalamic, and reticular electrodes. Drugs were infused intravenously at a constant rate up to a final cumulative dose of 40, 50, or 60 mg/kg. Doses of 10 mg/kg imipramine, viloxazine, desmethylimipramine, mianserin, and maprotiline produced spike-wave complexes, spikes, and increased spindling. General sustained discharges occurred after 20 mg/kg of mianserin, viloxazine, imipramine, desmethylimipramine and amitriptyline, and after 30 mg/kg of maprotiline. An abnormal high-amplitude pattern was evident after mianserin, amitriptyline, imipramine, and desmethylimipramine. On the average, seizures were observed at 40 mg/kg and were seen after desmethylimipramine (50 mg/kg), mianserin (30 mg/kg), amitriptyline (20 mg/kg), imipramine (40 mg/kg), maprotiline (40 mg/kg), and zimelidine (50 mg/kg). Ranking the tested antidepressants in decreasing order in accordance with their relative (pro)convulsive properties gives: amitriptyline greater than mianserin much greater than imipramine greater than desmethylimipramine greater than viloxazine much greater than maprotiline much greater than zimelidine greater than clovoxamine greater than nomifensine = fluvoxamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442931     DOI: 10.1159/000118147

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  13 in total

Review 1.  Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; A Ward
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

Review 2.  Spotlight on fluvoxamine in anxiety disorders in children and adolescents.

Authors:  Susan M Cheer; David P Figgitt
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Evaluation of Oogenesis Aspects in Neonatal and Adult Mice after Toloaldoxime Treatment.

Authors:  Mohammad Fazeltabar Malekshah; Mahsa Sedighi; Kazem Parivar; Homa Mohseni Kouchesfahani; Mohamadali Bigdeli
Journal:  Cell J       Date:  2015-10-07       Impact factor: 2.479

Review 4.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 5.  Selecting an antidepressant for use in a patient with epilepsy. Safety considerations.

Authors:  S Curran; K de Pauw
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 6.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 7.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

8.  Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model.

Authors:  Kinga K Borowicz; Monika Banach; Radosław Zarczuk; Dariusz Lukasik; Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Psychopharmacology (Berl)       Date:  2007-07-26       Impact factor: 4.530

Review 9.  Clinical originality and new biology of trimipramine.

Authors:  M Gastpar
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 10.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.